Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

NCT06558604 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Obinutuzumab
DRUG: Glofitamab
DRUG: Venetoclax Oral Product
DRUG: Zanubrutinib Oral Capsule

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]
[object Object]